Drugs / [18F]F-RESCA-RCCB6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06852638 | Dec 2024 → Dec 2026 expected | clear cell renal carcinoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]F-RESCA-RCCB6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06852638 ↗ |
| Modality | Diagnostic / imaging agent | “CD70-targeted immunoPET/CT imaging” NCT06852638 ↗ |
| Route | Other | “after \[18F\]RCCB6 injection” NCT06852638 ↗ |